iA Global Asset Management Inc. Lowers Stake in IQVIA Holdings Inc. (NYSE:IQV)

iA Global Asset Management Inc. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 94.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,160 shares of the medical research company's stock after selling 20,452 shares during the quarter. iA Global Asset Management Inc.'s holdings in IQVIA were worth $228,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Wilkins Investment Counsel Inc. grew its position in shares of IQVIA by 630.2% in the fourth quarter. Wilkins Investment Counsel Inc. now owns 54,657 shares of the medical research company's stock valued at $10,741,000 after purchasing an additional 47,172 shares during the period. Vinva Investment Management Ltd grew its position in shares of IQVIA by 9.4% during the 4th quarter. Vinva Investment Management Ltd now owns 9,110 shares of the medical research company's stock valued at $1,799,000 after buying an additional 786 shares during the last quarter. Intech Investment Management LLC increased its position in IQVIA by 159.2% in the fourth quarter. Intech Investment Management LLC now owns 2,444 shares of the medical research company's stock worth $480,000 after buying an additional 1,501 shares during the period. Generali Asset Management SPA SGR bought a new stake in IQVIA during the 4th quarter valued at $2,004,000. Finally, Tocqueville Asset Management L.P. increased its stake in shares of IQVIA by 6.3% during the fourth quarter. Tocqueville Asset Management L.P. now owns 26,147 shares of the medical research company's stock valued at $5,138,000 after acquiring an additional 1,547 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Remove Ads

IQVIA Price Performance

Shares of IQVIA stock traded down $4.73 during midday trading on Tuesday, hitting $181.38. 749,440 shares of the company traded hands, compared to its average volume of 1,239,209. The stock has a market cap of $31.98 billion, a price-to-earnings ratio of 24.20, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm's fifty day moving average price is $194.58 and its 200-day moving average price is $207.73. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $254.54.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on IQV shares. Bank of America reduced their target price on IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. Stifel Nicolaus dropped their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. William Blair reiterated an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Robert W. Baird lowered their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Finally, JPMorgan Chase & Co. cut their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.